The Economic Times

JM Financial sees up to 28% upside in Dr Reddys and Aurobindo Pharma. Should you buy?

JM Financial retained Buy ratings on Dr Reddys Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The brokerage expects stronger earnings growth, business diversification and new product launches to support both drugmakers.